Recent Updates
Recently added Catalysts

BNP7787

Phase 3

Breast Neoplasms | Small molecule | Oncology |Lantern Pharma Inc.|Last Updated: Jul 13, 2022

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment764
FDA Designations
No designations recorded
Clinical trial landscape

BNP7787 · 1 trial · 3 indications

Phase 3 1
NCT00039780Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly PaclitaxelBreast Neoplasms
COMPLETED764 Analytics
PHASE3COMPLETED
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel
Breast Neoplasms
NCT00039780764
Unlock trial analytics
Study Endpoints
Primary Endpoints
1)Incidence of PNQ Grade D or Grade E neurosensory symptoms (Item 1 of the PNQ) with duration of at least 4 weks; 2) Objective tumor response rate
baseline to disease progression or discontinuation from study
Secondary Endpoints
Incidence of Dose Modifications, Treatment Delays and Treatment Discontinuations due to Neurotoxicity
baseline to end of treatment
Time-to-onset of clinically important neurotoxicity
randomization to date of first occurrence of clinically important neurotoxicity
Incidence of Neurosensory and Neuromotor Functional Impairment
baseline through end of treatment
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
1ACTIVE_COMPARATORTavocept (BNP7787)
2PLACEBO_COMPARATOR0.9% Sodium Chloride Soln.
Interventions
NameTypeDescription
BNP7787DRUGThe treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
PlaceboDRUGThe treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexFEMALE
Healthy VolunteersNo

INCLUSION CRITERIA Histologically or cytologically documented metastatic breast cancer Measurable disease Performance Status; ECOG 0-2 More than 2 weeks since prior radiation therapy 14 days or more since prior therapy and recovered from all side effects For patients who progress while receivi...

Unlock Eligibility Criteria